Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Real Time Quote from BATS)

$7.73 USD

7.73
1,331,308

-0.09 (-1.15%)

Updated Apr 29, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

by Zacks Equity Research

Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

Ironwood/Allergan Settle Linzess Patent Litigation With Mylan

by Zacks Equity Research

Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.

Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.

Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -171.43% and -28.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance

by Zacks Equity Research

Allergan (AGN) beats third-quarter estimates for earnings and sales and raises its full-year guidance for both the metrics. Botox remains the primary sales driver.

Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Q3 Earnings Preview: Here's What to Look Out For

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

by Zacks Equity Research

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.

    Ironwood Stock Up, Heart Candidate Gets Fast Track Status

    by Zacks Equity Research

    The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.

      Why Is Ironwood (IRWD) Up 0.9% Since Last Earnings Report?

      by Zacks Equity Research

      Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Ironwood's Linzess Gets Approval in Japan for New Indication

        by Zacks Equity Research

        Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.

          Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

          by Zacks Equity Research

          Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

            Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

            by Zacks Equity Research

            Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

              Ironwood Pharmaceuticals (IRWD) Reports Q2 Loss, Lags Revenue Estimates

              by Zacks Equity Research

              Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                Ironwood Begins New Phase III Study to Expand Linzess Label

                by Zacks Equity Research

                Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

                  Ironwood Initiates Phase III Studies on Reflux Candidate

                  by Zacks Equity Research

                  Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

                    Ironwood Pharmaceuticals (IRWD) Down 10.3% Since Earnings Report: Can It Rebound?

                    by Zacks Equity Research

                    Ironwood Pharmaceuticals (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

                      by Zacks Equity Research

                      Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

                        Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

                        by Zacks Equity Research

                        Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

                          Ironwood Succeeds in Diabetic Hypertension Phase II Study

                          by Zacks Equity Research

                          Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

                            Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

                            by Zacks Equity Research

                            Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                              Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

                              by Zacks Equity Research

                              Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

                                Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?

                                by Zacks Equity Research

                                Ironwood (IRWD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Ironwood Pharma's Combination Gout Drug Gets FDA Approval

                                  by Zacks Equity Research

                                  Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.